alln-346
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2020 (NCT04236219)
Timeline
Indications
Mechanism of action
- Uric acidDEGRADER
Uric acid degrader
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05168683 | Phase 1 | Jan 11, 2022 | Allena Pharmaceuticals, BDD Pharma Ltd |
| NCT04987294 | Phase 2 | Aug 31, 2021 | Allena Pharmaceuticals |
| NCT04987242 | Phase 2 | Jul 16, 2021 | Allena Pharmaceuticals |
| NCT04829435 | Phase 1 | Apr 21, 2021 | Allena Pharmaceuticals |
| NCT04236219 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2020 | Allena Pharmaceuticals |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allena Pharmaceuticals | For profit | 5 | 5 | 2 | 2020 |
| BDD Pharma Ltd | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1